WO2022125007A1 - Prolonged release mirabegron formulations - Google Patents

Prolonged release mirabegron formulations Download PDF

Info

Publication number
WO2022125007A1
WO2022125007A1 PCT/TR2020/051260 TR2020051260W WO2022125007A1 WO 2022125007 A1 WO2022125007 A1 WO 2022125007A1 TR 2020051260 W TR2020051260 W TR 2020051260W WO 2022125007 A1 WO2022125007 A1 WO 2022125007A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
mirabegron
prolonged release
solid pharmaceutical
release solid
Prior art date
Application number
PCT/TR2020/051260
Other languages
French (fr)
Inventor
Erol KIRESEPI
Ersin Yildirim
Original Assignee
Santa Farma Ilac Sanayii A. S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Farma Ilac Sanayii A. S. filed Critical Santa Farma Ilac Sanayii A. S.
Priority to PCT/TR2020/051260 priority Critical patent/WO2022125007A1/en
Publication of WO2022125007A1 publication Critical patent/WO2022125007A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Definitions

  • the present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient in which release profile of the active ingredient is controlled by using a specific hydrophobic polymer and a plasticizer at a specific range of ratio in the coating formulation.
  • Overactive bladder is defined by The International Continence as urgency, with or without urgency incontinence, usually with frequency and nocturia. There is lack of information why overactive bladder occurs, but it is known that it involves detrusor overactivity which is responsible for feeling urgency by involving afferent signaling conveyed as bladder sensations.
  • overactive bladder There are many options for treatment of overactive bladder such as; bladder training and drug therapy using anticholinergic substances such as propiverine hydrochloride and oxybutynin hydrochloride have been mostly used at present. However, intractable cases and side effects could be occurred such as urinary dysfunction and dry mouth and, therefore, Mirabegron has been reported as one of the substance for the management of overactive bladder.
  • Mirabegron is a selective agonist for human beta 3 -adrenoceptor (beta 3 -AR) which is also dominant in the human detrusor muscle.
  • Beta 3 -AR human beta 3 -adrenoceptor
  • Mirabegron has been firstly declared by the Astellas Pharma Inc to be used for the treatment for diabetes, due to having an activity of promoting insulin secretion and enhancing insulin sensitivity, and also having an antiobestic activity and an antihyperlipemic activity.
  • Mirabegron can be used as an overactive bladder, such as overactive bladder accompanied by prostatic hyperplasia, or overactive bladder accompanied by urinary urgency, urinary incontinence, and urinary frequency.
  • Mirabegron is 2-(2-Amino-l,3-thiazoI-4-yl)-N-[4-(2- ⁇ [(2R)-2-hydroxy- 2-phenylethyl] amino ⁇ ethyl )phenyl] acetamide and the empirical formula is C2JH24N4O2S.
  • the compound has a molecular weight of 396.506 g/mol.
  • the structural formula of Mirabegron is shown in the Formula I.
  • Mirabegron appears as a white crystalline powder and non-hygroscopic. It can freely soluble in dimethyl sulfoxide, soluble in methanol and soluble in water between neutral to acidic pH, thus it is categorized as BCS III Drug which means that Mirabegron exhibits high solubility and low permeability.
  • Mirabegron has one chiral center and exhibits stereoisomerism.
  • the manufacture of the finish product consists of the R-enantiomer.
  • Mirabegron and its pharmaceutically acceptable salts thereof first have been described in EP1028111 numbered patent document by Yamanouchi Pharmaceutical Co. for the treatment of the Diabetes Mellitus.
  • Example 41 discloses the preparation of mirabegron and its pharmaceutically acceptable salt thereof, with hydrochloride salt.
  • patent document numbered as EP1559427 was first disclosed a pharmaceutical composition comprising mirabegron that can be used as a therapeutic agent for overactive bladder, such as overactive bladder accompanied by prostatic hyperplasia, or overactive bladder accompanied by urinary urgency, urinary incontinence, and urinary frequency.
  • the marketed product contains R-enantiomer of mirabegron was first described in patent document numbered as EP2298752, wherein an a-form crystal of mirabegron R- enantiomer has a moisture holding amount of not more than 0.2% and has main peaks at around 5.32, 8.08, 15.28, 17.88, 19.04, 20.20, 23.16 and 24.34 in the terms of 29(°) in the powder X- ray diffraction.
  • Mirabegron is in the prolonged released film coated tablet dosage form to control the drug release from the tablet which lead to more slower absorption rate in the gastrointestinal tract than immediate release formulations, even in fasted conditions, due to pharmacokinetic variation of mirabegron according to the presence or absence of food intake.
  • the rate of decrease in Cmax and AUC is 45% and 17%, respectively, when there is a coadministration with high fat meal.
  • that decreasing is not higher when there is a coadministration with low fat meal which decreased Mirabegron Cmax and AUC by 75% and 51%, respectively.
  • EP2554168 relates to a pharmaceutical composition for modified release comprising mirabegron or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein the dissolution rate of the drug from the composition is 75% or less after 1.5 hours from the beginning of the dissolution test, and also wherein the pharmaceutical composition is not a sustained release hydrogel formulation which contains an additive that allows water to penetrate into the formulation, and a hydrogel-forming polymer.
  • EP2345410 relates to a pharmaceutical composition for modified release comprising mirabegron, at least one additive having a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less to ensure penetration of water into the pharmaceutical composition, and a hydrogel-forming polymer having an average molecular weight of approximately 100.000 or more, or a viscosity of 12 mPa.s or more at a 5% aqueous solution at 25°C.
  • EP3278801 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a complex of mirabegron with sodium polystyrene sulfonate, a thickener, and a hydrophobic substance, wherein the hydrophobic substance is magnesium stearate and/or calcium stearate.
  • EP2832730 relates to a pharmaceutical composition for modified release comprising mirabegron dodecyl sulfate wherein a molar ratio of Mirabegron to alkyl sulfuric acid is 1 : 1 to 1:2.
  • WO201 1122523 relates to a pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, and the drug dissolution rate after 30 minutes from the beginning of the dissolution test is less than 85%.
  • EP3345600 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising mirabegron, hypromellose, and polyvinylpyrrolidone, wherein the spray-dried granulated product contains 100% or more by mass of the hypromellose, and the polyvinylpyrrolidone in total with respect to a content of the mirabegron.
  • W02019072404 relates to a pharmaceutical composition for modified release comprising; mirabegron presenting 5-25 wt% to the total weight of the uncoated tablet, polyethylene oxide having an average molecular weight of approximately 7,000,000 or a viscosity of 7500 to 10000 cps at a 1% aqueous solution at 25°C and polyethylene glycol having an average molecular weight of approximately 6000 to 10000, preferably 8000, wherein the weight ratio polyethylene oxide to polyethylene glycol ranges from 1:3 to 1:4.5;
  • EP3448366 relates to a pharmaceutical composition for modified release comprising; 5 to 25 wt%, relative to the total weight of mirabegron, 15 to 40 wt%, relative to the total weight, of a mixture of one or more polyethylene oxides having a viscosity of 100 to 800, preferably 400 to 800 cP at a 2% aqueous solution at 25°C, and a water insoluble hydrophilic excipient.
  • EP3554480 relates to a solid prolonged release solid pharmaceutical oral dosage form comprising mirabegron or a pharmaceutically acceptable salt thereof wherein Mirabegron is distributed in a sustained release matrix comprising a hydrogel generator selected from the group consisting of a mixture of at least two different hydroxypropyl methylcellulose, of alginate, alginic acid, poly (meth) acrylate -based polymer and carrageenan, and wherein dissolution rate of the drug from the composition is 20% to 40% in 3 hours, 44% to 64% in 5 hours and more than 80% in 8.5 h.
  • a hydrogel generator selected from the group consisting of a mixture of at least two different hydroxypropyl methylcellulose, of alginate, alginic acid, poly (meth) acrylate -based polymer and carrageenan, and wherein dissolution rate of the drug from the composition is 20% to 40% in 3 hours, 44% to 64% in 5 hours and more than 80% in 8.5 h.
  • WO2018169325 relates to a controlled release pharmaceutical composition
  • a controlled release pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof and a polyethylene oxide as a sustained release agent.
  • the prepared pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient in a prolonged release profile by using a hydrophobic polymer with a plasticizer in a range ratio of 1:0.5 - 1:1 in the film coating layer.
  • the object of this invention is to develop a prolonged release solid pharmaceutical composition
  • a prolonged release solid pharmaceutical composition comprising a therapeutically effective amount of mirabegron or one of its pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient.
  • It is an object of the present invention is to develop a prolonged release solid pharmaceutical composition comprising mirabegron or one of its pharmaceutically acceptable salts, which is used in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
  • the present invention is to develop a prolonged release solid composition comprising mirabegron and at least one pharmaceutically acceptable excipient manufactured by using wet granulation process.
  • Another object of the present invention is to develop preparation method of a pharmaceutical composition of Mirabegron wherein the pharmaceutical compositions herein disclosed can be manufactured into solid dosage forms, such as tablet, capsule, granule, powder.
  • Another object of the present invention is related to a pharmaceutical composition
  • a pharmaceutical composition comprising mirabegron and at least one pharmaceutically acceptable excipient and a functional film coating including a hydrophobic polymer and a plasticizer.
  • Another object of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a hydrophobic polymer and a plasticizer in a range ratio of 1:0.5 - 1:1 in the coating film layer to provide prolonged release of mirabegron throughout the entire gastrointestinal tract.
  • the present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient.
  • Mirabegron is a human P3 -adrenoceptor agonist which has been used for the management of overactive bladder syndrome for decades. Mirabegron exhibits high solubility and low permeability. Thus, after oral administration it is rapidly absorbed, but its absolute bioavailability is low and it slightly increased 29% at a 25 mg dose and 35% at a 50 mg dose. Besides that, there is another restriction about its bioavailability when given with food or absence of food throughout gastrointestinal tract.
  • a pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, wherein the variation in bioavailability caused by the presence or absence of food intake throughout gastrointestinal tract is minimized by controlling the drug release.
  • the composition comprising mirabegron or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient is presented as prolonged release tablet dosage form.
  • Prolonged release refers to any composition or dosage form which comprises active ingredient and which is formulated to provide a longer duration of pharmacological response after administration of the dosage form than is ordinarily experienced after administration of a corresponding immediate release composition comprising the same drug in the same amount.
  • Prolonged release is a continuous release of the active ingredient in a period of time of greater than about 1 hour, preferably greater than about 4 hours, more preferably, greater than about 8 hours.
  • the term “prolonged release” can be conveniently replaced by similar terms like modified release, controlled release, timed release, retarded release, extended release and delayed release, sustained release, programmed release and/or rate controlled dosage forms.
  • Suitable solid oral dosage forms are selected from the group comprising tablet, capsule, granule, powder, preferably the solid oral dosage form is tablet.
  • a hydrophobic polymer is designated for continuous drug release in the human gastrointestinal tract with diffusion of dissolving drug through a network of channels that exist between compacted polymer particles.
  • the hydrophobic polymer may include, but are not limited to, polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and their copolymers.
  • the hydrophobic polymer is selected as ethyl cellulose.
  • ethyl cellulose In the development dosage forms with modified release, ethyl cellulose is the perfect polymer to ensure drug dissolution throughout gastrointestinal tract and provide constant drug concentration. As the mechanism of action of ethyl cellulose, being insoluble at any gastrointestinal fluid at any pH, it undergoes to swell in these environments. As a result, it plays a significant role to improve the therapeutic effectiveness. In the present invention, it is used to provide the release of a drug in a controlled manner by using as an agent in coating formulation.
  • Ethyl cellulose is a biocompatible, non-allergenic, nonirritant, colorless, odorless, and tasteless hydrophobic polymer soluble in a wide variety of organic solvents such as alcohols, ketones, and polycyclic aromatic hydrocarbons, or solvent mixture to produce water insoluble films, but it does not dissolve in water, glycerin, or propylene glycol.
  • Ethyl cellulose effect can be modified by using in combination with a proper plasticizer in a specific ratio. Moreover, wherein plasticizer molecules are built in amongst the polymer chains that may cause to shift along each other in order to increasing the elasticity of the polymer film.
  • the compatibility between the excipients is quite important in order to reduce potential reduction between excipients which may affect the chemical, physical, bioavailability and stability of the dosage form.
  • ethyl cellulose is known to be quite compatible polymer with a wide array of excipients and most of the plasticizer.
  • the plasticizer may include, but are not limited triethyl citrate, acetyltriethyl citrate, tributyl citrate, and acetyltributyl citrate and the like and mixtures thereof.
  • the plasticizer is selected as triethyl citrate.
  • compositions comprising Mirabegron by using wet granulation process wherein provided for the manufacture of tablets containing the active ingredient, hydrophobic polymer binder, antioxidant, plasticizer, glidant and lubricant and solvent selected as to be the most suitable ones with respect to the intended form of administration.
  • the binder may include, but are not limited to dibasic calcium phosphate dihydrate, polysaccharides, microcrystalline cellulose, lactose and the like and mixtures thereof.
  • the binder is microcrystalline cellulose.
  • the antioxidant may include, but are not limited to butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, sodium sulfite, sodium thiosulfate, monothioglycerol, tert-butyl hydroquinone, ethoxyquin, dithiothreitol, and derivatives thereof.
  • the antioxidant is butylated hydroxy toluene.
  • the lubricant may include, but are not limited to magnesium stearate, zinc stearate, calcium stearate, talc, carnauba wax, stearic acid, sodium stearyl fumarate sodium laurel sulfate, glyceryl palmitostearate, and hydrogenated vegetable oils and fats, as well as other known lubricants.
  • the lubricant is magnesium stearate.
  • the glidant may include, but are not limited to silicon dioxide, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc and other known glidant.
  • the glidant is colloidal silicon dioxide.
  • the solvent may include, but are not limited deionized water, methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, ethyl acetate, dimethylsulfoxide and their mixtures thereof.
  • the solvent is deionized water.
  • the embodiment in accordance with the present invention was designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using wet granulation process.
  • Example 1 The embodiment identified as Example 1 was given in the Table- 1 below.
  • Another object of the present invention relates to provide wet granulation process for preparing a prolonged release pharmaceutical composition, providing the steps of: i. Mirabegron, Microcrystalline cellulose and Butylated hydroxytoluene were screened through a proper sieve and transferred into high-shear mixer and stirred, ii. Ethyl cellulose was dissolved in sufficient quantity of deionized water and added to the preparation in Step i to perform granulation process, iii. The granules prepared in Step ii were dried in fluid bed dryer and shifted through a proper sieve, iv. Colloidal silicon dioxide was screened through a proper sieve and added to the granules prepared in Step iii and stirred, v.
  • Magnesium stearate was screened through a proper sieve and added to the granules prepared in Step iv and stirred to obtain a uniform final blend, vi. Tablet compression was performed with the final blend in Step v. vii.
  • the coating was formulated separately including 1:0.5 - 1:1 ratio of ethyl cellulose and triethyl citrate, then it was applied to tablets prepared in Step vi.
  • the coating film layer is applied after the core tablet is prepared by using wet granulation process wherein the coating consists of ethyl cellulose as a hydrophobic polymer which is insoluble in water and gastro-intestinal fluids and triethyl citrate as a plasticizer in the ratio of

Abstract

The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient in which release profile of the active ingredient is controlled by using a specific hydrophobic polymer and a plasticizer at a specific range of ratio in the coating formulation.

Description

PROLONGED RELEASE MIRABEGRON FORMULATIONS
FIELD OF INVENTION
The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient in which release profile of the active ingredient is controlled by using a specific hydrophobic polymer and a plasticizer at a specific range of ratio in the coating formulation.
BACKGROUND OF THE INVENTION
Overactive bladder is defined by The International Continence as urgency, with or without urgency incontinence, usually with frequency and nocturia. There is lack of information why overactive bladder occurs, but it is known that it involves detrusor overactivity which is responsible for feeling urgency by involving afferent signaling conveyed as bladder sensations.
There are many options for treatment of overactive bladder such as; bladder training and drug therapy using anticholinergic substances such as propiverine hydrochloride and oxybutynin hydrochloride have been mostly used at present. However, intractable cases and side effects could be occurred such as urinary dysfunction and dry mouth and, therefore, Mirabegron has been reported as one of the substance for the management of overactive bladder.
Mirabegron is a selective agonist for human beta 3 -adrenoceptor (beta 3 -AR) which is also dominant in the human detrusor muscle. However, Mirabegron has been firstly declared by the Astellas Pharma Inc to be used for the treatment for diabetes, due to having an activity of promoting insulin secretion and enhancing insulin sensitivity, and also having an antiobestic activity and an antihyperlipemic activity. But then, it has been reported that Mirabegron can be used as an overactive bladder, such as overactive bladder accompanied by prostatic hyperplasia, or overactive bladder accompanied by urinary urgency, urinary incontinence, and urinary frequency.
The chemical name of Mirabegron is 2-(2-Amino-l,3-thiazoI-4-yl)-N-[4-(2-{[(2R)-2-hydroxy- 2-phenylethyl] amino} ethyl )phenyl] acetamide and the empirical formula is C2JH24N4O2S. The compound has a molecular weight of 396.506 g/mol. The structural formula of Mirabegron is shown in the Formula I.
Figure imgf000003_0001
Formula I
Mirabegron appears as a white crystalline powder and non-hygroscopic. It can freely soluble in dimethyl sulfoxide, soluble in methanol and soluble in water between neutral to acidic pH, thus it is categorized as BCS III Drug which means that Mirabegron exhibits high solubility and low permeability.
Mirabegron has one chiral center and exhibits stereoisomerism. The manufacture of the finish product consists of the R-enantiomer.
Mirabegron and its pharmaceutically acceptable salts thereof first have been described in EP1028111 numbered patent document by Yamanouchi Pharmaceutical Co. for the treatment of the Diabetes Mellitus. In particular, Example 41 discloses the preparation of mirabegron and its pharmaceutically acceptable salt thereof, with hydrochloride salt.
Moreover, patent document numbered as EP1559427 was first disclosed a pharmaceutical composition comprising mirabegron that can be used as a therapeutic agent for overactive bladder, such as overactive bladder accompanied by prostatic hyperplasia, or overactive bladder accompanied by urinary urgency, urinary incontinence, and urinary frequency.
Furthermore, the marketed product contains R-enantiomer of mirabegron was first described in patent document numbered as EP2298752, wherein an a-form crystal of mirabegron R- enantiomer has a moisture holding amount of not more than 0.2% and has main peaks at around 5.32, 8.08, 15.28, 17.88, 19.04, 20.20, 23.16 and 24.34 in the terms of 29(°) in the powder X- ray diffraction.
A pharmaceutical final product comprising mirabegron as an active was first approved in Japan and has been launched under the brand name of BETANIS®. In a similar way, it was commercially approved by the U.S. Food&Drug Administration in June 2012 and by European Medicines Agency in December 2012 and has been launched under the brand name of the MYRBETRIQ® in the United States and BETMIGA® in the Europe. All of the approved products are available as modified release tablet dosage form in the strength of 25 mg or 50 mg of mirabegron for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Mirabegron is in the prolonged released film coated tablet dosage form to control the drug release from the tablet which lead to more slower absorption rate in the gastrointestinal tract than immediate release formulations, even in fasted conditions, due to pharmacokinetic variation of mirabegron according to the presence or absence of food intake. For instance, the rate of decrease in Cmax and AUC is 45% and 17%, respectively, when there is a coadministration with high fat meal. However, that decreasing is not higher when there is a coadministration with low fat meal which decreased Mirabegron Cmax and AUC by 75% and 51%, respectively.
In the state of art there are many patents/patent applications which are summarized below.
EP2554168 relates to a pharmaceutical composition for modified release comprising mirabegron or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein the dissolution rate of the drug from the composition is 75% or less after 1.5 hours from the beginning of the dissolution test, and also wherein the pharmaceutical composition is not a sustained release hydrogel formulation which contains an additive that allows water to penetrate into the formulation, and a hydrogel-forming polymer.
EP2345410 relates to a pharmaceutical composition for modified release comprising mirabegron, at least one additive having a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less to ensure penetration of water into the pharmaceutical composition, and a hydrogel-forming polymer having an average molecular weight of approximately 100.000 or more, or a viscosity of 12 mPa.s or more at a 5% aqueous solution at 25°C.
EP3278801 relates to a pharmaceutical composition comprising a complex of mirabegron with sodium polystyrene sulfonate, a thickener, and a hydrophobic substance, wherein the hydrophobic substance is magnesium stearate and/or calcium stearate.
EP2832730 relates to a pharmaceutical composition for modified release comprising mirabegron dodecyl sulfate wherein a molar ratio of Mirabegron to alkyl sulfuric acid is 1 : 1 to 1:2. WO201 1122523 relates to a pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, and the drug dissolution rate after 30 minutes from the beginning of the dissolution test is less than 85%.
EP3345600 relates to a pharmaceutical composition comprising mirabegron, hypromellose, and polyvinylpyrrolidone, wherein the spray-dried granulated product contains 100% or more by mass of the hypromellose, and the polyvinylpyrrolidone in total with respect to a content of the mirabegron.
W02019072404 relates to a pharmaceutical composition for modified release comprising; mirabegron presenting 5-25 wt% to the total weight of the uncoated tablet, polyethylene oxide having an average molecular weight of approximately 7,000,000 or a viscosity of 7500 to 10000 cps at a 1% aqueous solution at 25°C and polyethylene glycol having an average molecular weight of approximately 6000 to 10000, preferably 8000, wherein the weight ratio polyethylene oxide to polyethylene glycol ranges from 1:3 to 1:4.5;
EP3448366 relates to a pharmaceutical composition for modified release comprising; 5 to 25 wt%, relative to the total weight of mirabegron, 15 to 40 wt%, relative to the total weight, of a mixture of one or more polyethylene oxides having a viscosity of 100 to 800, preferably 400 to 800 cP at a 2% aqueous solution at 25°C, and a water insoluble hydrophilic excipient.
EP3554480 relates to a solid prolonged release solid pharmaceutical oral dosage form comprising mirabegron or a pharmaceutically acceptable salt thereof wherein Mirabegron is distributed in a sustained release matrix comprising a hydrogel generator selected from the group consisting of a mixture of at least two different hydroxypropyl methylcellulose, of alginate, alginic acid, poly (meth) acrylate -based polymer and carrageenan, and wherein dissolution rate of the drug from the composition is 20% to 40% in 3 hours, 44% to 64% in 5 hours and more than 80% in 8.5 h.
WO2018169325 relates to a controlled release pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof and a polyethylene oxide as a sustained release agent.
Although there are many patent applications of various patent applications, there is a need to develop a pharmaceutical composition comprising mirabegron that capable of avoiding the effects of food intake with a prolonged release based on a functional film coating including hydrophobic polymer and a plasticizer.
In the present invention, the prepared pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient in a prolonged release profile by using a hydrophobic polymer with a plasticizer in a range ratio of 1:0.5 - 1:1 in the film coating layer.
SUMMARY OF THE INVENTION
The object of this invention is to develop a prolonged release solid pharmaceutical composition comprising a therapeutically effective amount of mirabegron or one of its pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient.
It is an object of the present invention is to develop a prolonged release solid pharmaceutical composition comprising mirabegron or one of its pharmaceutically acceptable salts, which is used in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The present invention is to develop a prolonged release solid composition comprising mirabegron and at least one pharmaceutically acceptable excipient manufactured by using wet granulation process.
Another object of the present invention is to develop preparation method of a pharmaceutical composition of Mirabegron wherein the pharmaceutical compositions herein disclosed can be manufactured into solid dosage forms, such as tablet, capsule, granule, powder.
Another object of the present invention is related to a pharmaceutical composition comprising mirabegron and at least one pharmaceutically acceptable excipient and a functional film coating including a hydrophobic polymer and a plasticizer.
Another object of the present invention relates to a pharmaceutical composition comprising a hydrophobic polymer and a plasticizer in a range ratio of 1:0.5 - 1:1 in the coating film layer to provide prolonged release of mirabegron throughout the entire gastrointestinal tract.
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a prolonged release formulation comprising mirabegron or a pharmaceutically acceptable salt thereof as active ingredient.
Mirabegron is a human P3 -adrenoceptor agonist which has been used for the management of overactive bladder syndrome for decades. Mirabegron exhibits high solubility and low permeability. Thus, after oral administration it is rapidly absorbed, but its absolute bioavailability is low and it slightly increased 29% at a 25 mg dose and 35% at a 50 mg dose. Besides that, there is another restriction about its bioavailability when given with food or absence of food throughout gastrointestinal tract.
Therefore, in the present invention relates to a pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, wherein the variation in bioavailability caused by the presence or absence of food intake throughout gastrointestinal tract is minimized by controlling the drug release. The composition comprising mirabegron or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient is presented as prolonged release tablet dosage form.
The term "prolonged release" herein refers to any composition or dosage form which comprises active ingredient and which is formulated to provide a longer duration of pharmacological response after administration of the dosage form than is ordinarily experienced after administration of a corresponding immediate release composition comprising the same drug in the same amount. Prolonged release is a continuous release of the active ingredient in a period of time of greater than about 1 hour, preferably greater than about 4 hours, more preferably, greater than about 8 hours. The term “prolonged release” can be conveniently replaced by similar terms like modified release, controlled release, timed release, retarded release, extended release and delayed release, sustained release, programmed release and/or rate controlled dosage forms.
In a preferred embodiment of the present invention is to provide a pharmaceutical composition for oral administration. Suitable solid oral dosage forms are selected from the group comprising tablet, capsule, granule, powder, preferably the solid oral dosage form is tablet.
In a preferred embodiment of prolonged release solid dosage composition, a hydrophobic polymer is designated for continuous drug release in the human gastrointestinal tract with diffusion of dissolving drug through a network of channels that exist between compacted polymer particles. In the preferred embodiment of the present invention, the hydrophobic polymer may include, but are not limited to, polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and their copolymers. Preferably, the hydrophobic polymer is selected as ethyl cellulose.
In the development dosage forms with modified release, ethyl cellulose is the perfect polymer to ensure drug dissolution throughout gastrointestinal tract and provide constant drug concentration. As the mechanism of action of ethyl cellulose, being insoluble at any gastrointestinal fluid at any pH, it undergoes to swell in these environments. As a result, it plays a significant role to improve the therapeutic effectiveness. In the present invention, it is used to provide the release of a drug in a controlled manner by using as an agent in coating formulation.
Ethyl cellulose is a biocompatible, non-allergenic, nonirritant, colorless, odorless, and tasteless hydrophobic polymer soluble in a wide variety of organic solvents such as alcohols, ketones, and polycyclic aromatic hydrocarbons, or solvent mixture to produce water insoluble films, but it does not dissolve in water, glycerin, or propylene glycol.
Ethyl cellulose effect can be modified by using in combination with a proper plasticizer in a specific ratio. Moreover, wherein plasticizer molecules are built in amongst the polymer chains that may cause to shift along each other in order to increasing the elasticity of the polymer film.
The compatibility between the excipients is quite important in order to reduce potential reduction between excipients which may affect the chemical, physical, bioavailability and stability of the dosage form. According to the literature knowledge, ethyl cellulose is known to be quite compatible polymer with a wide array of excipients and most of the plasticizer. Thus, in the preferred embodiment of the present invention, the plasticizer may include, but are not limited triethyl citrate, acetyltriethyl citrate, tributyl citrate, and acetyltributyl citrate and the like and mixtures thereof. Preferably, the plasticizer is selected as triethyl citrate.
In one of the preferred embodiment of the present invention is to provide a pharmaceutical compositions comprising Mirabegron by using wet granulation process wherein provided for the manufacture of tablets containing the active ingredient, hydrophobic polymer binder, antioxidant, plasticizer, glidant and lubricant and solvent selected as to be the most suitable ones with respect to the intended form of administration.
In the preferred embodiment of the present invention, the binder may include, but are not limited to dibasic calcium phosphate dihydrate, polysaccharides, microcrystalline cellulose, lactose and the like and mixtures thereof. Preferably, the binder is microcrystalline cellulose. In the preferred embodiment of the present invention, the antioxidant may include, but are not limited to butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, sodium sulfite, sodium thiosulfate, monothioglycerol, tert-butyl hydroquinone, ethoxyquin, dithiothreitol, and derivatives thereof. Preferably, the antioxidant is butylated hydroxy toluene.
In the preferred embodiment of the present invention, the lubricant may include, but are not limited to magnesium stearate, zinc stearate, calcium stearate, talc, carnauba wax, stearic acid, sodium stearyl fumarate sodium laurel sulfate, glyceryl palmitostearate, and hydrogenated vegetable oils and fats, as well as other known lubricants. Preferably, the lubricant is magnesium stearate.
In the preferred embodiment of the present invention, the glidant may include, but are not limited to silicon dioxide, colloidal silicon dioxide, magnesium silicate, magnesium trisilicate, talc and other known glidant. Preferably, the glidant is colloidal silicon dioxide.
In the preferred embodiment of the present invention, the solvent may include, but are not limited deionized water, methanol, ethanol, isopropyl alcohol, dichloromethane, acetone, ethyl acetate, dimethylsulfoxide and their mixtures thereof. Preferably, the solvent is deionized water.
The embodiment in accordance with the present invention was designed with adjusted quantitative composition composed of pharmaceutically acceptable ingredients mentioned above by using wet granulation process.
The embodiment identified as Example 1 was given in the Table- 1 below.
The proposed embodiment based on the invention provides a prolonged release solid pharmaceutical composition is as stated below:
Table 1: Unit Formula of Example 1
Figure imgf000009_0001
Another object of the present invention relates to provide wet granulation process for preparing a prolonged release pharmaceutical composition, providing the steps of: i. Mirabegron, Microcrystalline cellulose and Butylated hydroxytoluene were screened through a proper sieve and transferred into high-shear mixer and stirred, ii. Ethyl cellulose was dissolved in sufficient quantity of deionized water and added to the preparation in Step i to perform granulation process, iii. The granules prepared in Step ii were dried in fluid bed dryer and shifted through a proper sieve, iv. Colloidal silicon dioxide was screened through a proper sieve and added to the granules prepared in Step iii and stirred, v. Magnesium stearate was screened through a proper sieve and added to the granules prepared in Step iv and stirred to obtain a uniform final blend, vi. Tablet compression was performed with the final blend in Step v. vii. The coating was formulated separately including 1:0.5 - 1:1 ratio of ethyl cellulose and triethyl citrate, then it was applied to tablets prepared in Step vi.
The coating film layer is applied after the core tablet is prepared by using wet granulation process wherein the coating consists of ethyl cellulose as a hydrophobic polymer which is insoluble in water and gastro-intestinal fluids and triethyl citrate as a plasticizer in the ratio of
1:0.5 - 1:1 by weight.
Table 2: Composition of Film coating layer for Example 1
Figure imgf000010_0001
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

1. A prolonged release solid pharmaceutical composition comprising mirabegron or a pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable excipient and a film coating layer comprising hydrophobic polymer and a plasticizer, wherein the weight ratio of hydrophobic polymer to plasticizer is between 1:0.5 - 1:1.
2. A prolonged release solid pharmaceutical composition according to Claim 1, wherein the hydrophobic polymer is selected from polyethylene, polyvinyl chloride, ethyl cellulose, acrylate polymers and their copolymers.
3. A prolonged release solid pharmaceutical composition according to claims 1 or 2, wherein the hydrophobic polymer is ethyl cellulose.
4. A prolonged release solid pharmaceutical composition according to any one of the preceding claims, wherein the plasticizer is selected from triethyl citrate, acetyltriethyl citrate, tributyl citrate, acetyltributyl citrate and mixtures thereof.
5. A prolonged release solid pharmaceutical composition according to any one of the preceding claims, wherein the plasticizer is triethyl citrate.
6. A prolonged release solid pharmaceutical composition according to Claim 1, wherein at least one pharmaceutically acceptable excipient is selected from filler, disintegrant, glidant, surfactant, lubricant and mixtures thereof.
7. A prolonged release solid pharmaceutical composition according to any one of the preceding claims, wherein the composition is prepared by wet granulation method.
8. A prolonged release solid pharmaceutical composition according to any one of the preceding claims for use in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
PCT/TR2020/051260 2020-12-08 2020-12-08 Prolonged release mirabegron formulations WO2022125007A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/TR2020/051260 WO2022125007A1 (en) 2020-12-08 2020-12-08 Prolonged release mirabegron formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2020/051260 WO2022125007A1 (en) 2020-12-08 2020-12-08 Prolonged release mirabegron formulations

Publications (1)

Publication Number Publication Date
WO2022125007A1 true WO2022125007A1 (en) 2022-06-16

Family

ID=81974491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2020/051260 WO2022125007A1 (en) 2020-12-08 2020-12-08 Prolonged release mirabegron formulations

Country Status (1)

Country Link
WO (1) WO2022125007A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025848A1 (en) * 1997-09-30 2000-08-09 Nikken Chemicals Company, Limited Sustained-release theophylline tablet
EP2832730A1 (en) * 2012-03-30 2015-02-04 Astellas Pharma Inc. Mirabegron-containing pharmaceutical composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025848A1 (en) * 1997-09-30 2000-08-09 Nikken Chemicals Company, Limited Sustained-release theophylline tablet
EP2832730A1 (en) * 2012-03-30 2015-02-04 Astellas Pharma Inc. Mirabegron-containing pharmaceutical composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADELEKE, O. A.: "Premium ethylcellulose polymer based architectures at work in drug delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS: X, 1, 100023, 2019, XP055951914 *
AGRAWAL, A. M. ET AL.: "Wet granulation fine particle ethylcellulose tablets: effect of production variables and mathematical modeling of drug release", AAPS PHARMSCI, vol. 5, no. 2, 2003, pages 48 - 60, XP035718641, DOI: 10.1208/ps050213 *
DASHEVSKY, A. ET AL.: "Compression of pellets coated with various aqueous polymer dispersions", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 279, no. 1-2, 2004, pages 19 - 26, XP055951911 *
HUNG, S. F. ET AL.: "Characterizations of plasticized polymeric film coatings for preparing multiple-unit floating drug delivery systems (muFDDSs) with controlled-release characteristics", PLOS ONE, vol. 9, no. 6, 2014, XP055951912 *

Similar Documents

Publication Publication Date Title
US9180101B2 (en) Pharmaceutical composition simultaneously having rapid-acting property and long-acting property
US5266331A (en) Controlled release oxycodone compositions
JP5816091B2 (en) Sodium oxybate immediate release dosage form
CA2652712C (en) Stabilized pharmaceutical compositions comprising fesoterodine
US8778397B2 (en) Stabilized tolterodine tartrate formulations
RU2572695C2 (en) Application of binding agents to obtain stable in storage compositions
JPH11505542A (en) Triphasic pharmaceutical formulation with constant and controlled release of amorphous active ingredient for once daily dosing
KR100678421B1 (en) Controlled-release formulation containing tamsulosin hydrochloride
US20160287541A1 (en) Modified Release Tranexamic Acid Formulation
BG107372A (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
CA2555295C (en) Extended release coated mini-tablets of venlafaxine hydrochloride
KR20190064215A (en) Pharmaceutical Composition Comprising Tofacitinib
WO2022125007A1 (en) Prolonged release mirabegron formulations
WO2014096982A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
WO2008032208A2 (en) Extended release formulation of an antiepileptic agent
KR20210012082A (en) A pharmaceutical composition comprising mirabegron and tamsulosin
WO2014096983A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
TR2023006080T2 (en) EXTENDED RELEASE MIRABEGRON FORMULATIONS
WO2023113706A1 (en) Pharmaceutical composition comprising mirabegron in matrix form
IE883894L (en) Synergistic combination of decarboxylase inhibitors and L-dopa pellets
WO2023080855A1 (en) Pharmaceutical composition comprising mirabegron and calcium salts
KR20160141044A (en) Extended Release Formulation for Oral Administration of Sildenafil
WO2010112221A1 (en) Pharmaceutical compositions comprising memantine
WO2006136927A1 (en) Extended release formulations comprising venlafaxine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20965251

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20965251

Country of ref document: EP

Kind code of ref document: A1